Navigation Links
American Society of Clinical Oncology (ASCO) Accepts New Data on,AVR118 for Publication in 2007 Abstract Book

YONKERS, N.Y.--(BUSINESS WIRE)--Mar 7, 2007 - Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, announced today that new information on AVR118 has been accepted for publication in the 2007 Proceedings of the American Society of Clinical Oncology (ASCO) Abstract publication. This publication will be distributed to the nearly 25,000 oncology practioners who will be attending this year's meeting in Chicago on June 1-5.

Based on recent work conducted by ADVR, new insight has been made regarding the chemical composition of AVR118. As a result of these findings, clinicians will have a better understanding of how AVR118 exerts its clinical effects, whether it is administered topically or systemically. Additionally, this work may provide clues on how new formulations of AVR118 may be produced with greater activity in a variety of different clinical applications.

"Based on our new understanding of how AVR118 exerts its cytoprotective effects, we are in a much better position to understand how it might be used more effectively to stimulate appetite, improve fatigue, and assist in rapidly reversing the toxic side-effects of chemo, radiation and possibly even interferon therapies. We now have evidence that it binds to adenosine receptors in-vitro and increases cAMP release in several different cell lines. Its anti-anorexic activity may involve targeted receptor binding in the gut and in the functional pathway of orexin A. AVR118 has also shown a 20% enhancement of epitheliazation when compared to saline controls in a controlled porcine wound healing model" says, Dr. J. T. D'Olimpio, author of the abstract.

"Based on our improved understanding of the composition of AVR118, we are in a much better position to predict the potential clinical indications for our product," says Stephen M. Elliston, CEO and President of Advanced Viral Research Corp. "Up until now there has been a major unmet need for new non-toxic orexigenic and cytoprotective agents that can ameliorate some of the intractable symptoms associated with cancer related cachexia. Today, we are increasingly optimistic that AVR118 might provide a much needed alternative to existing therapies," added Elliston.

Advanced Viral Research Corp. is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the systematic control of symptoms associated with cancer and other serious diseases. ADVR's lead product, AVR118 represents a new class of complex cytoprotective agents that target among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models.

Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV/AIDS and chronic inflammation are potential disease targets for AVR118 therapy.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

For further information regarding Advanced Viral Research Corp., please Visit our website at http://www.adviral.com.

Contact

Equity Relations, Inc.
Richard Brown, 617-314-7379
staff@equityrelations.com


'"/>




Related medicine technology :

1. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
7. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
10. Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes
11. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... know that PhRMA member companies invested $65.5 billion in research and ... generics and the supply chain account for 14 percent of total ... (7 percent)? Or that the United States ... high-growth biopharmaceutical startups? ... The biopharmaceutical industry accounts for 1 ...
(Date:7/19/2017)... July 19, 2017  Mako Medical Laboratories partnered with ... Military Family Assistance Fund (MFA) to bring 140 soldiers ... visit with their families one last time before being ... the travel and logistics needed for these soldiers. "Mako ... and their families. We just wish we could bring ...
(Date:7/15/2017)... July 15, 2017 Enterin Inc., a ... Parkinson,s disease (PD), today announced the completion of a $12.7 ... New Ventures III, as well as the participation of existing ... thrilled to have the support of New Ventures III and ... as validation of the potential of our platform technology to ...
Breaking Medicine Technology:
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... is pleased to now offer a major advancement in drug therapy for patients ... Ocrevus (pronounced Ah-creh-vus) is a novel B cell targeted therapy that has ...
(Date:7/26/2017)... ... July 26, 2017 , ... It may be hard to imagine ... to people in the third world. Diseases that many developed countries consider rare or ... don't have access to vaccines. , On an upcoming segment of "Success Files", actor ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... on-premises, off and in the cloud ; today announced the availability of its ... within a simple to use control console for Data Discovery, Classification, Encryption and ...
(Date:7/26/2017)... ... , ... IDC-Eating Disorder Care is excited to announce Dr. Tracey ... Oak, Michigan. IDC, formerly known as Inner Door Center, was acquired in ... in the field of eating disorder treatment in the state of Michigan. ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... has released an updated version of the HCV Treatment Path app (version 4.4.0) ... hepatitis C virus (HCV) infection. All of the latest HCV medications are included ...
Breaking Medicine News(10 mins):